



Contact:

Mike Gaynes
Kalaheo Consulting, Inc.
650-728-0227
kalaheo.consulting@yahoo.com

**Neuronetics Strengthens Commercialization Team with New Vice President of
Marketing**

— Suzanne McMonigle joins Senior Management Team—

Malvern, PA, January 6, 2012 – Neuronetics, Inc., today announced that Suzanne McMonigle, an industry executive with more than 20 years of experience in marketing and sales leadership, has been appointed as Vice President, Marketing. In her new role, Sue will lead marketing efforts for Neuronetics, including NeuroStar TMS (transcranial magnetic stimulation) Therapy[®], a non-invasive neuromodulation treatment for adults with major depressive disorder who have not benefitted from initial antidepressant medication.

“Sue brings incredible depth in marketing to both clinicians and patients, along with a track record of serial success. We are pleased to welcome her to our senior management team,” said Bruce Shook, President and Chief Executive Officer of Neuronetics. “We are confident that Sue will bring great strength to the marketing team, the senior management team, and the Company as a whole.”

Prior to joining Neuronetics, Ms. McMonigle held the position of Worldwide Vice President of Sales & Marketing at Animas Corporation of West Chester, PA. Animas is an insulin pump company and is part of the Diabetes Care Franchise within Johnson and Johnson. Animas operates in 20 markets with a significant direct to patient marketing model. Sue was promoted to Worldwide Vice President Sales and Marketing at Animas in 2010 from her previous position of Vice President, Marketing.

Sue started her career with IBM in sales and later moved on to consumer marketing within RJR Nabisco and Procter & Gamble. At Procter & Gamble, she successfully marketed several consumer based drug products and rose to the position of Global Brand Manager for Actonel, a highly successful osteoporosis drug.

She then joined Centocor, a biotechnology company owned by Johnson and Johnson, where she became the Senior Marketing Director for the Worldwide Dermatology franchise. At Centocor, Sue was marketing various biologic products for in office use by dermatologists. Sue then moved to Animas, where she successfully increased their market share in the highly competitive insulin pump market.

Sue has a BS in Business Administration from Fordham University and an MBA from Cornell University.

“The potential for broadly improving the awareness of NeuroStar TMS Therapy is enormous. I believe my experience marketing to both clinicians and patients will be instrumental in advancing the development of the NeuroStar business,” said McMonigle. “It is truly an honor to join a company that markets a product that provides an opportunity for so many people to improve their lives.”

About NeuroStar TMS Therapy

Neuronetics' NeuroStar TMS Therapy system was cleared by the FDA in October 2008 for the treatment of Major Depressive Disorder. NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that has been linked to depression by delivering highly focused MRI-strength magnetic field pulses. The treatment is typically administered daily for 4-6 weeks. For full safety and prescribing information, visit www.NeuroStarTMS.com.

Availability of NeuroStar TMS Therapy

Treatment with NeuroStar TMS Therapy is available at more than 380 treatment centers in 48 states. For information on specific treatment locations that offer NeuroStar TMS Therapy, please visit www.NeuroStar.com or call Neuronetics Customer Service Center at (877) 600-7555.

About Neuronetics

Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation. Neuronetics was created as a spinout of The Innovation Factory, a medical device incubator in Duluth, GA. For more information, please visit www.neuronetics.com.

1. Demitrack MA, Thase ME, *Psychopharmacology Bulletin* 2009; 42(2):5-38.

NeuroStar[®], NeuroStar TMS Therapy[®], and TMS Therapy[®] are registered trademarks of Neuronetics, Inc.

####